[Precision Oncology Options in Urological Cancers]

Overview

Journal Urologie

Specialty Urology

Date 2023 Jun 9

PMID 37294331

Authors

Antonia Franz

Henning Plage

Annika Fendler

Thorsten Schlomm

Kira Kornienko

Affiliations

Soon will be listed here.

Abstract

Advancements in the molecular genetic understanding of urological tumors have enabled the identification of numerous new therapeutic targets. Based on routinely applicable tumor sequencing, individual treatment decisions have been introduced in the context of precision oncology. This work provides an overview of the latest targeted tumor therapies in the treatment of prostate cancer, urothelial carcinoma, and renal cell carcinoma. Current studies on the administration of FGFR-inhibitors ("fibroblast growth factor receptor") in metastatic urothelial carcinoma show a high tumor response in patients with selected FGFR alterations. PARP-inhibitors ("Poly-[ADP-Ribose-]Polymerase") are routinely used in the treatment of metastatic prostate cancer. Patients with a BRCA mutation ("BReast CAncer gene") show high radiological response rates. Moreover, we discuss the latest results of the combination of PARP inhibitors with novel androgen receptor pathway inhibitors. In metastatic prostate cancer, there are numerous ongoing studies evaluating the promising drug targets PI3K/AKT/mTOR ("Phosphatidylinositol-3-Kinase")/AKT/mTOR ("mammalian target of rapamycine") and VEGF signaling pathways ("vascular endothelial growth factor"). A HIF-2a inhibitor ("hypoxia inducible factor") offers a promising new therapeutic option for metastatic renal cell carcinoma. Overall, molecular diagnostics to determine the right therapy for the right patient subgroup at the right time is important for uro-oncological precision medicine.

References

Ornitz D, Itoh N . The Fibroblast Growth Factor signaling pathway. Wiley Interdiscip Rev Dev Biol. 2015; 4(3):215-66. PMC: 4393358. DOI: 10.1002/wdev.176. View

Johnson D, Williams L . Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res. 1993; 60:1-41. DOI: 10.1016/s0065-230x(08)60821-0. View

Hernandez S, Lopez-Knowles E, Lloreta J, Kogevinas M, Amoros A, Tardon A . Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol. 2006; 24(22):3664-71. DOI: 10.1200/JCO.2005.05.1771. View

Kamoun A, De Reynies A, Allory Y, Sjodahl G, Robertson A, Seiler R . A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur Urol. 2019; 77(4):420-433. PMC: 7690647. DOI: 10.1016/j.eururo.2019.09.006. View

Kim K, Hu W, Audenet F, Almassi N, Hanrahan A, Murray K . Modeling biological and genetic diversity in upper tract urothelial carcinoma with patient derived xenografts. Nat Commun. 2020; 11(1):1975. PMC: 7181640. DOI: 10.1038/s41467-020-15885-7. View

Stein J, Lieskovsky G, Cote R, Groshen S, Feng A, Boyd S . Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001; 19(3):666-75. DOI: 10.1200/JCO.2001.19.3.666. View

Loriot Y, Necchi A, Park S, Garcia-Donas J, Huddart R, Burgess E . Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2019; 381(4):338-348. DOI: 10.1056/NEJMoa1817323. View

Sternberg C, Petrylak D, Bellmunt J, Nishiyama H, Necchi A, Gurney H . FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on / mRNA Expression. J Clin Oncol. 2022; 41(3):629-639. PMC: 9870218. DOI: 10.1200/JCO.21.02303. View

Javle M, Roychowdhury S, Kelley R, Sadeghi S, Macarulla T, Weiss K . Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol. 2021; 6(10):803-815. DOI: 10.1016/S2468-1253(21)00196-5. View

10.

Jing W, Wang G, Cui Z, Xiong G, Jiang X, Li Y . FGFR3 Destabilizes PD-L1 via NEDD4 to Control T-cell-Mediated Bladder Cancer Immune Surveillance. Cancer Res. 2021; 82(1):114-129. DOI: 10.1158/0008-5472.CAN-21-2362. View

11.

Palakurthi S, Kuraguchi M, Zacharek S, Zudaire E, Huang W, Bonal D . The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity. Cancer Immunol Res. 2019; 7(9):1457-1471. DOI: 10.1158/2326-6066.CIR-18-0595. View

12.

de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S . Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020; 382(22):2091-2102. DOI: 10.1056/NEJMoa1911440. View

13.

Robinson D, Van Allen E, Wu Y, Schultz N, Lonigro R, Mosquera J . Integrative clinical genomics of advanced prostate cancer. Cell. 2015; 161(5):1215-1228. PMC: 4484602. DOI: 10.1016/j.cell.2015.05.001. View

14.

Pritchard C, Mateo J, Walsh M, De Sarkar N, Abida W, Beltran H . Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med. 2016; 375(5):443-53. PMC: 4986616. DOI: 10.1056/NEJMoa1603144. View

15.

Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I . Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci U S A. 2019; 116(23):11428-11436. PMC: 6561293. DOI: 10.1073/pnas.1902651116. View

16.

Horak P, Weischenfeldt J, von Amsberg G, Beyer B, Schutte A, Uhrig S . Response to olaparib in a germline mutated prostate cancer and genetic events associated with resistance. Cold Spring Harb Mol Case Stud. 2019; 5(2). PMC: 6549578. DOI: 10.1101/mcs.a003657. View

17.

Clarke N, Wiechno P, Alekseev B, Sala N, Jones R, Kocak I . Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2018; 19(7):975-986. DOI: 10.1016/S1470-2045(18)30365-6. View

18.

Krohn A, Diedler T, Burkhardt L, Mayer P, De Silva C, Meyer-Kornblum M . Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Am J Pathol. 2012; 181(2):401-12. DOI: 10.1016/j.ajpath.2012.04.026. View

19.

Jamaspishvili T, Berman D, Ross A, Scher H, De Marzo A, Squire J . Clinical implications of PTEN loss in prostate cancer. Nat Rev Urol. 2018; 15(4):222-234. PMC: 7472658. DOI: 10.1038/nrurol.2018.9. View

20.

Sweeney C, Bracarda S, Sternberg C, Chi K, Olmos D, Sandhu S . Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2021; 398(10295):131-142. DOI: 10.1016/S0140-6736(21)00580-8. View